Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE LA 120 50 versus MAXZIDE 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERIDE LA 120 50 versus MAXZIDE 25.
INDERIDE LA 120/50 vs MAXZIDE-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propranolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium reabsorption and promoting diuresis.
Maxzide-25 is a combination of hydrochlorothiazide, a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, and triamterene, a potassium-sparing diuretic that inhibits sodium reabsorption in the collecting duct by blocking epithelial sodium channels.
One capsule orally once daily, containing 120 mg propranolol HCl and 50 mg hydrochlorothiazide.
1 tablet (triamterene 37.5 mg/hydrochlorothiazide 25 mg) orally once daily.
None Documented
None Documented
Propranolol: 3-6 hours; Hydrochlorothiazide: 6-15 hours. Note: Inderide LA is an extended-release formulation; effective half-life extended to approximately 8-12 hours for propranolol component.
Triamterene: 2-4 hours (terminal half-life due to active metabolite hydroxylated triamterene, clinical effect persists 12-16 hours). Hydrochlorothiazide: 5.6-14.8 hours (mean 8.5 hours).
Primarily hepatic metabolism (90%+), with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for negligible amounts.
Renal: triamterene 80-85% (as metabolites, 5-10% unchanged), hydrochlorothiazide ≥95% unchanged via tubular secretion; biliary/fecal: minimal (<5% each).
Category C
Category C
Beta-Blocker/Diuretic Combination
Diuretic Combination